3 Things In Biotech, March 30: Amgen Hunts, Exelixis Moves On Europe, Cynata Enters The Fray


Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. News: AMGN announced that the FDA has approved its supplemental application for blinatumomab for use in patients with acute lymphoblastic leukemia who have so-called "minimal residual disease," which is a strong risk factor for relapse.



from Biotech News